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BACKGROUND Rupture of lipid core plaque (LCP) is central to the pathology of an
acute coronary syndrome (ACS). Intracoronary near-infrared spectroscopy (NIRS) has
been shown to identify lipid core plaque (LCP) in patients undergoing coronary
angiography (CA) in ACS. Studies using NIRS have shown that acute, intensive statin
therapy reduces lipid core burden index (LCBI), a surrogate for lipid content in LCP.
We aimed to determine if chronic long term statin use affects lipid content of LCP as
measured by NIRS.
METHODS Forty-seven consecutive patients undergoing CA and NIRS with intravas-
cular ultrasonography for at least one obstructive lesion were included. Lipid core
burden index, LCBI divided by the length of scanned artery LCBI/L and the MaxLCBI
4mm (maximum value of LCBI for any of the 4-mm segment) were obtain from the
scan of the three vessel except the left main and stented segment. Baseline patient
characteristics and medication use was recorded. The patients receiving long-term
treatment by statin before hospitalization (n¼28) were compared with those without
(n¼19).
RESULTS Patients had a mean age of 64.4 years with a prevalence of men (70.2%),
diabetic (40.4%), hypercholesterolemia (89%) and smoking history (10%). In the
group receiving statin, 10 patients had Atorvastatin (10 to 80 mg), 10 Rosuvastatin (5
to 40 mg) and 8 Simvastatin (10 to 40 mg). No signiﬁcant difference was found for all
NIRS’s parameters in the both groups.Group statin (n[28) Group without statin (n[19) PLCBI (average) 116.1 113.63 0.46LCBI/L(average) 3.4 2.31 0.19MaxLCBI 4mm (average) 397.46 443.63 0.31CONCLUSION Although the intensive statin therapy decreases the LCBI, the presence
of statin with usual doses before performing NRIS does not appear to predict the result
of LCBI. The control by spectroscopy in the same patient on the occasion of new angi-
ography after statin dose optimization should be a goodway for assesses its risk of ACS.
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BACKGROUND It has been well known that a major cause of vasospastic angina is
endothelial dysfunction and subsequent signiﬁcant coronary vasoconstriction. Thus,
diltiazem and nitrate can be beneﬁcial as selective coronary vasodilators for pts with
signiﬁcant vasoconstriction. However, there is no study comparing the efﬁcacy of
diltiazem alone versus diliazem with nitrate treatment for long-term clinical out-
comes in vasospastic angina pts.
METHODS A total of 3,360 consecutive pts without signiﬁcant coronary artery disease
(CAD) underwent acetylcholine (Ach) provocation test between Nov. 2004 and May.
2014 and positive coronary artery spasm (CAS) pts were enrolled. Signiﬁcant CAS was
deﬁned as > 70% of narrowing by incremental intracoronary injection of 20, 50 and
100 mg into left coronary artery. Pts were divided into two groups: the diltiazem group
(n¼842), the dual group (diltiazemþnitrate, n¼1,899). To adjust potential con-
founders, a propensity score matched (PSM) analysis was performed using the logistic
regression model.
RESULTS After PSM analysis, 2 propensity-matched groups (811 pairs, n ¼ 1,622, C-
statistic¼0.708) were generated and the baseline characteristics of the two groups
were balanced. At 5 years, there were similar incidence of individual hard endpoints
including mortality, myocardial infarction, revascularization and recurrent angina
requiring repeat coronary angiography between the two groups (Table and Figure).CONCLUSIONS Despite the expected improvement of endothelial function and
relieving vasoconstriction, combination of diltiazem and nitrate treatment were not
superior to diltiazem alone in reducing clinical events and ischemic symptoms up to
5-year.
Table. Clinical Outcomes up to 5-years after Propensity Score Matching
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BACKGROUND Bivalirudin is a synthetic reversible inhibitor of thrombin and is
popularly used in the United States in patients undergoing percutaneous coronary
intervention (PCI). While the evidence shows a bleeding beneﬁt with bivalirudin
compared to heparin, there are concerns raised regarding the risk of peri-procedural
stent thrombosis. We aimed to quantify and analyze the incidence and predictors of
the risk of bleeding and stent thrombosis with bivalirudin.
METHODS We searched PubMed, the Cochrane library, and major meeting and jour-
nal abstracts for studies that reported events with bivalirudin use during PCI. Pooled
event rate (ER) and 95% conﬁdence intervals (CI) were calculated with random-ef-
fects for up to 30-day bleeding events and stent thrombosis.
RESULTS We identiﬁed 70 studies (n ¼ 71,299) that used bivalirudin as the anti-
coagulant of choice for PCI. Major bleeding events were noted in 1053 of 55636 (1.9%)
and minor bleeding were noted in 1104 of 24969 (4.4%) patients. Majority of bleeding
events were due to use of transfusion (1.6%) and access site bleeding (1.1%). Intra-
cranial and retroperitoneal bleeding were rare (<0.1%). Deﬁnite stent thrombosis
occurred in 266 of 29875 (0.9%) patients, of which majority were acute stent
thrombosis. Pooled event rates for bleeding and stent thrombosis are reported in the
ﬁgure. Majority of the studies did not report the acuity of stent thrombosis limiting
the analysis. On meta-regression analysis, the use of drug eluting stents (DES) was
associated with a lower risk of stent thrombosis (t ¼ -2.44, p ¼ 0.022).
CONCLUSIONS Bivalirudin is associated with a 2% risk of major and a 4.4% risk of
minor bleeding, majority of which are transfusion and access-site related. The risk of
stent thrombosis is around 0.9% and the use of DES decreases this risk.
